TRCT
ARCT icon

Tower Research Capital (TRC)’s Arcturus Therapeutics ARCT Stock Holding History

Tower Research Capital (TRC)’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.1K Buy
4,423
+4,298
+3,438% +$31.4K ﹤0.01% 3074
2025
Q4 		$766 Sell
125
-3,492
-97% -$37.7K ﹤0.01% 4823
2025
Q3 		$66.7K Buy
3,617
+1,046
+41% +$16.8K ﹤0.01% 2295
2025
Q2 		$33.4K Sell
2,571
-3,905
-60% -$46.2K ﹤0.01% 3320
2025
Q1 		$68.6K Buy
6,476
+6,169
+2,009% +$97.9K ﹤0.01% 1998
2024
Q4 		$5.21K Sell
307
-3,543
-92% -$66.7K ﹤0.01% 4332
2024
Q3 		$89.4K Buy
3,850
+809
+27% +$17.3K ﹤0.01% 2323
2024
Q2 		$74K Buy
3,041
+2,403
+377% +$72.9K ﹤0.01% 2803
2024
Q1 		$21.5K Sell
638
-8,944
-93% -$317K ﹤0.01% 2936
2023
Q4 		$302K Buy
9,582
+7,934
+481% +$189K ﹤0.01% 1767
2023
Q3 		$42.1K Sell
1,648
-10,969
-87% -$338K ﹤0.01% 2692
2023
Q2 		$362K Buy
12,617
+7,026
+126% +$191K 0.01% 1185
2023
Q1 		$134K Buy
5,591
+4,654
+497% +$83.5K ﹤0.01% 1614
2022
Q4 		$16K Sell
937
-2,790
-75% -$48.6K ﹤0.01% 3318
2022
Q3 		$55K Sell
3,727
-3,403
-48% -$57.1K ﹤0.01% 3072
2022
Q2 		$112K Buy
7,130
+6,795
+2,028% +$133K ﹤0.01% 2191
2022
Q1 		$9K Sell
335
-1,988
-86% -$50.7K ﹤0.01% 4429
2021
Q4 		$86K Sell
2,323
-2,463
-51% -$100K ﹤0.01% 2333
2021
Q3 		$229K Buy
4,786
+3,386
+242% +$152K 0.01% 1687
2021
Q2 		$47K Sell
1,400
-8,957
-86% -$303K ﹤0.01% 3063
2021
Q1 		$428K Buy
10,357
+1,992
+24% +$119K 0.01% 1370
2020
Q4 		$363K Buy
8,365
+4,303
+106% +$291K 0.01% 1247
2020
Q3 		$174K Buy
4,062
+3,335
+459% +$166K ﹤0.01% 2697
2020
Q2 		$34K Buy
+727
New +$25.1K ﹤0.01% 3348
2020
Q1 		– Sell
-3,569
Closed -$39K – 3010
2019
Q4 		$39K Buy
+3,569
New +$37.4K ﹤0.01% 1483
2019
Q3 		– Sell
-52
Closed – – 4061
2019
Q2 		$0 Buy
+52
New +$382 ﹤0.01% 3631
2019
Q1 		– Sell
-919
Closed -$4K – 3762
2018
Q4 		$4K Buy
919
+337
+58% +$2.07K ﹤0.01% 2993
2018
Q3 		$5K Buy
582
+536
+1,165% +$4.46K ﹤0.01% 3096
2018
Q2 		$0 Sell
46
-54
-54% -$350 ﹤0.01% 3612
2018
Q1 		$1K Buy
+100
New +$690 ﹤0.01% 3043
2017
Q1 		– Sell
-92
Closed -$1K – 3021
2016
Q4 		$1K Buy
+92
New +$1.38K ﹤0.01% 3559
2015
Q4 		– Sell
-111
Closed -$5K – 4437
2015
Q3 		$5K Buy
111
+19
+21% +$999 ﹤0.01% 2768
2015
Q2 		$4K Buy
92
+70
+318% +$3.21K ﹤0.01% 3342
2015
Q1 		$1K Buy
+22
New +$968 ﹤0.01% 4007
2014
Q4 		– Sell
-87
Closed -$9K – 3980
2014
Q3 		$9K Buy
87
+19
+28% +$2.48K ﹤0.01% 2877
2014
Q2 		$8K Buy
68
+60
+750% +$7.25K ﹤0.01% 2500
2014
Q1 		$1K Sell
8
-163
-95% -$24.2K ﹤0.01% 4101
2013
Q4 		$22K Buy
171
+138
+418% +$17.3K ﹤0.01% 2205
2013
Q3 		$4K Buy
+33
New +$2.94K ﹤0.01% 3767

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Tower Research Capital (TRC)'s ARCT Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Arcturus Therapeutics (ARCT) stake by 3,438% in Q1 2026, buying an estimated $31.4K and bringing the position to 4,423 shares worth $34.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3074.

Tower Research Capital (TRC) first reported a position in ARCT in Q3 2013 and has held it in 39 quarters since. The position peaked at $428K in Q1 2021. 124 funds tracked by Wall St. Rank hold ARCT as of Q1 2026.

  • Tower Research Capital (TRC) held 4,423 shares of Arcturus Therapeutics worth $34.1K as of Q1 2026.
  • Tower Research Capital (TRC) bought 4,298 Arcturus Therapeutics shares in Q1 2026, an estimated $31.4K.
  • Arcturus Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3074 holding.
  • Tower Research Capital (TRC) first reported a position in Arcturus Therapeutics in Q3 2013 and has held it in 39 quarters since.
  • Tower Research Capital (TRC)'s Arcturus Therapeutics position peaked at $428K in Q1 2021.
  • 124 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.